Primary insiders that were granted options have the following holdings of options and shares in the Company after the new share options were granted on 1th of February 2017 (new options in parenthesis):
Luigi Costa, CEO holds 1,338,106 options (250,000) and owns 79,115 shares
Tone Kvåle, CFO holds 315,000 options (105,000) and owns 179,608 shares including shares to related party
Marco Renoldi, COO holds 464,137 options (96,000) and owns 74,000 shares
Anniken Hagen, CTOO holds 177,000 options (35,000) and owns 63,858 shares
Lisa Rojkjaer, CMO holds 375,000 options (35,000) and owns 2,186 shares
Rita Dege, CHRO holds 67,000 options (35,000) and owns 4,754 shares
Jostein Dahle, CSO holds 150,000 options (15,000) and owns 204,958 shares including shares to related party
The options allocated to the management of the Company is in accordance with the Board of Director's Declaration on salaries and other remuneration to the senior executive management, as approved by the Company's annual general meeting held 19 May 2016. The total number of outstanding share options is now 3,509,676 equivalent to 6.7 % of outstanding shares and options on a fully diluted basis.
For further information, please contact:
Tone Kvåle, Chief Financial Officer
Phone: +47 91 51 95 76
About Nordic Nanovector:
Nordic Nanovector is a biotech company focusing on the development and commercialisation of novel targeted therapeutics in haematology and oncology. The Company's lead clinical-stage product opportunity is Betalutin®, the first in a new class of Antibody-Radionuclide-Conjugates (ARC) designed to improve upon and complement current options for the treatment of non-Hodgkin Lymphoma (NHL). NHL is an indication with substantial unmet medical need and orphan drug opportunities, representing a growing market worth over $12 billion by 2018.
Betalutin® comprises a tumour-seeking anti-CD37 antibody, lilotomab (previously referred to as HH1), conjugated to a low intensity radionuclide (lutetium-177). The preliminary data has shown promising efficacy and safety profile in an ongoing Phase 1/2 study in a difficult-to-treat NHL patient population. The Company is aiming at developing Betalutin® for the treatment of major types of NHL with first regulatory submission anticipated in 1H 2019.
Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets, while exploring potential distribution agreements in selected geographies. The Company is committed to developing its ARC pipeline to treat multiple selected cancer indications.
Further information about the Company can be found at www.nordicnanovector.com
This information is subject to duty of disclosure pursuant to Section 5-12 and 4-2 of the Norwegian Securities Trading Act.
This information was brought to you by Cision http://news.cision.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nordic-nanovector-share-options-granted-including-options-to-primary-insiders-300401079.html
SOURCE Nordic Nanovector